Zonulin

Zonulin (haptoglobin 2 precursor)^[1] is a protein that increases the permeability of tight junctions between cells of the wall of the digestive tract.^[2] It was discovered in 2000 by Alessio Fasano and his team at the University of Maryland School of Medicine. As the mammalian analogue of zonula occludens toxin, secreted by cholera pathogen Vibrio cholerae, zonulin has been implicated in the pathogenesis of coeliac disease and diabetes mellitus type 1.^[3] Type 2 diabetic patients have shown increased zonulin.^[4] However, in recent years, researchers in the field have called into question the existence of zonulin after discovering that the popular ELISA assay used to measure zonulin may have in fact been measuring different proteins across studies. These observations have led some in the field to conclude that zonulin is an ill-defined term encompassing potentially many different proteins and is therefore a poor biomarker of celiac disease.^[5]

Alessio Fasano

Gliadin (a glycoprotein present in gluten) activates zonulin signaling irrespective of the genetic expression of autoimmunity, leading to increased intestinal permeability of macromolecules.^[3][6]

Zonula occludens toxin is being studied as an adjuvant to improve absorption of drugs and vaccines.^[7] In 2014 a zonulin receptor antagonist, larazotide acetate (formerly known as AT-1001), completed a phase 2b clinical trial.^[8][9]

See also

• Leaky gut syndrome